Method for inhibiting angiogenesis with modified platelet factor-4 and cleaved platelet factor-4
AssigneeEli Lilly and Company
InventorsShalley K. Gupta, Jai P. Singh
Life of this patent
Estimating the term…
Abstract
The present invention is based of the discovery of two modified forms of human platelet factor-4, herein named MPF-4 and CPF-4, which were isolated from serum free culture medium of lipopolysaccharide-stimulated peripheral blood leukocytes. Amino acid sequence determination revealed that MPF-4 shares homology with platelet factor-4 beginning at N-terminal residue 17. CPF-4 consists of MPF-4 disulfide bonded to the 16 N-terminal residues of platelet factor-4. Both MPF-4 and CPF-4 are potent inhibitors of endothelial cell proliferation, approximately 10-100 fold more potent than native or recombinant platelet factor-4, making them useful in the treatment of angiogenic diseases.
Claims2
A method of inhibiting angiogenesis which comprises administering an effective amount of the a composition consisting essentially of modified platelet factor-4 (SEQ ID NO:
- 1).
A method of inhibiting angiogenesis which comprises administering an effective amount of the a composition consisting essentially of cleaved platelet factor-4 consisting of a protein having the amino acid sequence of SEQ ID NO:
- 1 having disulfide bonds to a second protein having the amino acid sequence of SEQ ID NO:
- 2, said disulfide bonds bridging Cys-20 of SEQ ID NO:
- 1 to Cys-10 of SEQ ID NO:
- 2 and Cys-36 of SEQ ID NO:
- 1 Cys-12 of SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.